DUBLIN – Quell Therapeutics Ltd., a new startup founded by the London-based biotech investment firm Syncona Ltd., has secured £35 million (US$44.5 million) in series A funding to progress the development of novel therapies based on engineering regulatory T cells (Tregs) to treat autoimmune disease and prevent organ transplant rejection.